BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 17659092)

  • 1. Application of the multicellular tumour spheroid model to screen PET tracers for analysis of early response of chemotherapy in breast cancer.
    Monazzam A; Josephsson R; Blomqvist C; Carlsson J; Långström B; Bergström M
    Breast Cancer Res; 2007; 9(4):R45. PubMed ID: 17659092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the Hsp90 inhibitor NVP-AUY922 in multicellular tumour spheroids with respect to effects on growth and PET tracer uptake.
    Monazzam A; Razifar P; Ide S; Rugaard Jensen M; Josephsson R; Blomqvist C; Langström B; Bergström M
    Nucl Med Biol; 2009 Apr; 36(3):335-42. PubMed ID: 19324279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modeling spheroid growth, PET tracer uptake, and treatment effects of the Hsp90 inhibitor NVP-AUY922.
    Bergstrom M; Monazzam A; Razifar P; Ide S; Josephsson R; Langstrom B
    J Nucl Med; 2008 Jul; 49(7):1204-10. PubMed ID: 18552146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of intercellular communications in breast cancer multicellular tumor spheroids after chemotherapy.
    Oktem G; Bilir A; Ayla S; Yavasoglu A; Goksel G; Saydam G; Uysal A
    Oncol Res; 2006; 16(5):225-33. PubMed ID: 17294803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 3D tumour spheroids as a model to assess the suitability of [18F]FDG-PET as an early indicator of response to PI3K inhibition.
    Kelly CJ; Hussien K; Muschel RJ
    Nucl Med Biol; 2012 Oct; 39(7):986-92. PubMed ID: 22682985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multicellular tumour spheroid as a model for evaluation of [18F]FDG as biomarker for breast cancer treatment monitoring.
    Monazzam A; Razifar P; Simonsson M; Qvarnström F; Josephsson R; Blomqvist C; Långström B; Bergström M
    Cancer Cell Int; 2006 Mar; 6():6. PubMed ID: 16556298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gef gene therapy enhances the therapeutic efficacy of doxorubicin to combat growth of MCF-7 breast cancer cells.
    Prados J; Melguizo C; Rama AR; Ortiz R; Segura A; Boulaiz H; Vélez C; Caba O; Ramos JL; Aránega A
    Cancer Chemother Pharmacol; 2010 May; 66(1):69-78. PubMed ID: 19771430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 3'-Deoxy-3'-[(18)F]fluorothymidine (FLT) uptake in breast cancer cells as a measure of proliferation after doxorubicin and docetaxel treatment.
    Dittmann H; Jusufoska A; Dohmen BM; Smyczek-Gargya B; Fersis N; Pritzkow M; Kehlbach R; Vonthein R; Machulla HJ; Bares R
    Nucl Med Biol; 2009 Feb; 36(2):163-9. PubMed ID: 19217528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biological basis of [¹¹C]choline-positron emission tomography in patients with breast cancer: comparison with [¹⁸F]fluorothymidine positron emission tomography.
    Contractor KB; Kenny LM; Stebbing J; Challapalli A; Al-Nahhas A; Palmieri C; Shousha S; Lewis JS; Hogben K; De Nguyen Q; Coombes RC; Aboagye EO
    Nucl Med Commun; 2011 Nov; 32(11):997-1004. PubMed ID: 21862943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 18F-fluoro-L-thymidine and 11C-methylmethionine as markers of increased transport and proliferation in brain tumors.
    Jacobs AH; Thomas A; Kracht LW; Li H; Dittmar C; Garlip G; Galldiks N; Klein JC; Sobesky J; Hilker R; Vollmar S; Herholz K; Wienhard K; Heiss WD
    J Nucl Med; 2005 Dec; 46(12):1948-58. PubMed ID: 16330557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of apoptosis and response of extracellular matrix proteins after chemotherapy application on human breast cancer cell spheroids.
    Oktem G; Vatansever S; Ayla S; Uysal A; Aktas S; Karabulut B; Bilir A
    Oncol Rep; 2006 Feb; 15(2):335-40. PubMed ID: 16391851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of positron emission tomographic tracers for imaging of papillomavirus-induced tumors in rabbits.
    Probst S; Wiehr S; Mantlik F; Schmidt H; Kolb A; Münch P; Delcuratolo M; Stubenrauch F; Pichler BJ; Iftner T
    Mol Imaging; 2014; 13():. PubMed ID: 24622808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of 18F-FES, 18F-FDG, and 18F-FMISO PET Imaging Probes for Early Prediction and Monitoring of Response to Endocrine Therapy in a Mouse Xenograft Model of ER-Positive Breast Cancer.
    He S; Wang M; Yang Z; Zhang J; Zhang Y; Luo J; Zhang Y
    PLoS One; 2016; 11(7):e0159916. PubMed ID: 27467716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pre-clinical validation of orthotopically-implanted pulmonary tumor by imaging with 18F-fluorothymidine-positron emission tomography/computed tomography.
    Fushiki H; Miyoshi S; Noda A; Murakami Y; Sasaki H; Jitsuoka M; Mitsuoka K; Matsunari I; Nishimura S
    Anticancer Res; 2013 Nov; 33(11):4741-9. PubMed ID: 24222108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo imaging of therapy response to a novel pan-HER antibody mixture using FDG and FLT positron emission tomography.
    Nielsen CH; Jensen MM; Kristensen LK; Dahlman A; Fröhlich C; Jacobsen HJ; Poulsen TT; Lantto J; Horak ID; Kragh M; Kjaer A
    Oncotarget; 2015 Nov; 6(35):37486-99. PubMed ID: 26460961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography.
    Kenny L; Coombes RC; Vigushin DM; Al-Nahhas A; Shousha S; Aboagye EO
    Eur J Nucl Med Mol Imaging; 2007 Sep; 34(9):1339-47. PubMed ID: 17333178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glioma proliferation as assessed by 3'-fluoro-3'-deoxy-L-thymidine positron emission tomography in patients with newly diagnosed high-grade glioma.
    Ullrich R; Backes H; Li H; Kracht L; Miletic H; Kesper K; Neumaier B; Heiss WD; Wienhard K; Jacobs AH
    Clin Cancer Res; 2008 Apr; 14(7):2049-55. PubMed ID: 18381944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Impact of [18F] FDG-PET in operable breast cancer treated with neoadjuvant chemotherapy.
    Jung SY; Kim SK; Nam BH; Min SY; Lee SJ; Park C; Kwon Y; Kim EA; Ko KL; Park IH; Lee KS; Shin KH; Lee S; Kim SW; Kang HS; Ro J
    Ann Surg Oncol; 2010 Jan; 17(1):247-53. PubMed ID: 19777177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Correlation of 3'-deoxy-3'-18F-fluorothymidine uptake to cell proliferation in lung carcinoma xenografts].
    Liu X; Zhou NK; Zhang JM; Liang ZY; Zheng X
    Ai Zheng; 2006 Dec; 25(12):1512-6. PubMed ID: 17166377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive value of FDG PET/CT for pathologic axillary node involvement after neoadjuvant chemotherapy.
    Keam B; Im SA; Koh Y; Han SW; Oh DY; Cho N; Kim JH; Han W; Kang KW; Moon WK; Kim TY; Park IA; Noh DY; Chung JK; Bang YJ
    Breast Cancer; 2013 Apr; 20(2):167-73. PubMed ID: 22311581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.